Clinical trial tests herpes virus-based therapy for neurogenic bladder in people with spinal cord injury

A modified herpes virus that targets spinal cord nerve cells to treat neurogenic bladder in people with spinal cord injury is underway in a first-in-human clinical trial by UTHealth Houston at TIRR Memorial Hermann.

GSK offers glimpse at RSV vaccine in at-risk younger adults before ACIP meeting

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 25, 2024

Study points out the need to recognize TBI as a chronic condition

People with TBI may continue to improve or decline years after their injury, making it a more chronic illness, according to a study published in

June 22, 2023

COVID-19 Risk Calculator updated to assess a person’s risk of developing long COVID

The University of Queensland-led and developed COVID-19 Risk Calculator has been updated to determine a person’s risk of developing long COVID.

July 31, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.